ArticleActa Cardiologica Sinica2026
Cocktail Therapy Combining SGLT2 Inhibitor, Entresto, and Adipose-Derived Mesenchymal Stem Cells Prevents Abdominal Aortic Aneurysmal Complication Syndrome in Rodents.
Article in Acta Cardiologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigated whether triple combination therapy [dapagliflozin (DAPA) + sacubitril/valsartan (Entresto) + adipose-derived mesenchymal stem cells (ADMSCs)] offered additional benefits on preventing complication syndrome [defined as abdominal aortic aneurysm (AAA) dilatation, muscle layer destruction and inflammation] in rodents with AAA. Methods: Adult male Sprague-Dawley rats (n = 54) were equally categorized into group 1 (sham control), group 2 (AAA only), group 3 [AAA + DAPA (20 mg/kg/day orally from days 7 to 28 after AAA induction)], group 4 [AAA + Entresto (100 mg/kg/day orally from days 7 to 28 after AAA induction)], group 5 [AAA + ADMSCs (1.0 × 10 Results: The results showed that the AAA diameter at day 28 was smallest in group 1, biggest in group 2, significantly larger in group 4 than in groups 3/5/6, and significantly larger in groups 4/5 than in group 6; however, there was no difference between groups 4 and 5 (all p < 0.0001). Light microscopic findings demonstrated that the AAA intimal thickness (i.e., indicator of intimal hyperplasia)/fibrotic area/number of immune-inflammatory [cluster of differentiation (CD) 3+/CD4+/matrix metalloproteinase [MMP] 2+/MMP9+] cells displayed an identical pattern, whereas the integrity of the laminar structure of AAA medial-muscle layer/number of small vessels exhibited an opposite pattern of AAA diameter among the groups (all p < 0.0001). The protein expressions of inflammation (tumor necrosis factor-alpha/interleukin (IL)-1 beta/IL-6/MMP2/MMP9)/fibrosis (transforming growth factor-beta/mothers against decapentaplegic homolog 3) markers displayed an identical pattern, whereas the protein expressions of tissue inhibitors of metalloproteinases (tissue inhibitor of metalloproteinases-1/tissue inhibitor of metalloproteinases-2) and apoptosis (cleaved-Caspase3/cleaved-poly(ADP-ribose) polymerase) displayed an opposite pattern of AAA diameter among the groups (all p < 0.0001). Conclusions: The results of the present study support that triple therapy with DAPA + Entresto + ADMSCs could be an innovative therapeutic modality for AAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.